Flu Babi

01Pathophysiology

H1N1 influenza ("swine flu") is caused by a reassortant Influenza A virus that contains gene segments derived from swine, avian, and human influenza strains. This antigenic shift (a major change in the hemagglutinin and/or neuraminidase surface glycoproteins) produced a novel virus to which the general population had little or no preexisting immunity. This is the reason the 2009 pandemic disproportionately affected younger individuals, as older adults had partial cross-reactive immunity from prior exposure to antigenically related H1N1 strains that circulated before 1957.

The virus enters the respiratory tract and binds to sialic acid residues on epithelial cells via the hemagglutinin (H) surface protein. After receptor-mediated endocytosis, the viral RNA is released and replicates within the host cell nucleus. The neuraminidase (N) surface protein then cleaves sialic acid to allow release of new virions, enabling spread to adjacent cells. This is the precise target of neuraminidase inhibitors like oseltamivir.

In severe cases, the virus triggers an exaggerated host immune response often described as a "cytokine storm." Pro-inflammatory cytokines (IL-6, TNF-alpha, IL-1beta) are released in excessive quantities, leading to diffuse alveolar damage, increased capillary permeability, pulmonary edema, and ultimately acute respiratory distress syndrome (ARDS). This explains why previously healthy young adults with robust immune systems paradoxically develop the most severe disease: their vigorous immune response causes more collateral lung damage.

The predilection for lower respiratory tract involvement distinguishes severe H1N1 from typical seasonal influenza, which tends to remain confined to the upper airways. The gastrointestinal symptoms (nausea, vomiting, diarrhea) seen more frequently in H1N1 correlate with the virus's ability to replicate in intestinal epithelial cells, a feature not as prominent in other seasonal influenza strains.

02Classification and Clinical Manifestation

By Severity

By Complication Type

03Diagnostic Workup

The best initial test in a clinical setting where rapid influenza detection is needed is the Rapid Influenza Diagnostic Test (RIDT) or, if available, a rapid molecular assay (such as the Xpert Flu). These provide results within 15 to 30 minutes and are useful for triage. However, the examiner expects you to know that RIDTs have poor sensitivity (40-70%) for H1N1, meaning a negative rapid test in a patient with a compatible clinical syndrome should not change your management.

The most accurate (confirmatory) test is real-time reverse transcriptase PCR (rRT-PCR) performed on a nasopharyngeal swab or aspirate. This test identifies the influenza A virus and subtypes it as H1N1. It has both high sensitivity and high specificity. When a vignette describes a patient with influenza-like illness during a known outbreak and asks for the "most accurate" or "confirmatory" test, the answer is rRT-PCR.

In terms of laboratory workup, patients with severe disease commonly show lymphopenia (an important clue that points away from bacterial infection, where you would expect neutrophilic leukocytosis). Elevated LDH, ferritin, and CRP serve as markers of disease severity and correlate with the degree of systemic inflammation. Thrombocytopenia may also be present.

For pulmonary assessment, a chest X-ray is the first imaging study. In primary viral pneumonia from H1N1, the classic pattern is bilateral diffuse patchy infiltrates or ground-glass opacities, often with a peripheral and lower lobe predominance. If a vignette describes a young adult with bilateral infiltrates and progressive hypoxemia, consider H1N1 pneumonia complicated by ARDS. The ratio $Pa{O}_2\mathrm{/}Fi{O}_{2}PaO\_2\; /\; FiO\_2$ from arterial blood gas analysis is used to stage ARDS severity according to the Berlin criteria.

04Management and Treatment

Acute stabilization begins with oseltamivir 75 mg orally twice daily, which should be started as early as possible and ideally within 48 hours of symptom onset. This is the single most important management step the exam will test. However, in hospitalized patients, severely ill patients, or those in high-risk groups (pregnant women, immunocompromised), antiviral therapy should be initiated even if more than 48 hours have elapsed since symptom onset, because late treatment still reduces mortality in these populations.

For the exam, remember: do not withhold oseltamivir in a high-risk or hospitalized patient just because they present after 48 hours. This is a frequently tested concept. The 48-hour window applies most strictly to otherwise healthy outpatients with mild disease.

Zanamivir (inhaled) is an alternative neuraminidase inhibitor, but it is contraindicated in patients with underlying airway disease (asthma, COPD) because it can induce bronchospasm. If a vignette presents an asthmatic patient with H1N1, the answer for treatment is oseltamivir, not zanamivir.

In critically ill patients who cannot take oral medications, peramivir 600 mg IV as a single dose is the preferred parenteral option. Baloxavir marboxil is a newer agent with a different mechanism (cap-dependent endonuclease inhibitor rather than neuraminidase inhibitor) given as a single oral dose, approved for uncomplicated influenza in patients aged 12 years and older.

For pregnant women, oseltamivir is the preferred antiviral and is considered safe in all trimesters. Zanamivir (inhaled) is an alternative but is less studied. The key teaching point: pregnancy is both a risk factor for severe H1N1 and a condition where you should not delay treatment.

Supportive management for severe pneumonia and ARDS follows standard critical care principles: supplemental oxygen titrated to $Sp{O}_2\ge 92\mathrm{\%}SpO\_2\; \backslash geq\; 92\backslash \%$, low tidal volume ventilation at 6 mL/kg of predicted body weight with plateau pressure below 30 cmH2O, and prone positioning for refractory hypoxemia. During the 2009 pandemic, ECMO was used as a rescue therapy for patients failing conventional mechanical ventilation and showed benefit in younger patients.

If there is clinical suspicion for secondary bacterial superinfection (recurrence of fever after initial improvement, new purulent sputum, leukocytosis with left shift, lobar consolidation on imaging), empiric antibiotics should cover Staphylococcus aureus (including MRSA) and Streptococcus pneumoniae. A common regimen includes vancomycin plus a beta-lactam with antipseudomonal coverage.

Post-exposure prophylaxis with oseltamivir (75 mg once daily for 10 days) is recommended for high-risk individuals who have had close contact with a confirmed case, particularly household contacts who are pregnant, immunosuppressed, or at extremes of age.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on H1N1 questions involves misunderstanding the 48-hour treatment window. Many examinees believe that oseltamivir is useless after 48 hours, which leads them to select "supportive care only" for a hospitalized patient presenting on day 3 of illness. In reality, for any patient who is hospitalized, severely ill, or belongs to a high-risk group (pregnant, immunocompromised, obese, extremes of age), oseltamivir should be started regardless of symptom duration.

A second common trap is the false-negative rapid test. A vignette may describe a classic influenza presentation during an outbreak, then state that the rapid influenza test is negative. The wrong answer is "influenza ruled out; pursue alternative diagnosis." The correct answer is to treat empirically with oseltamivir and send rRT-PCR for confirmation, because rapid tests lack sensitivity for H1N1.

Another tested concept is the age distribution. Unlike seasonal influenza, which causes the highest mortality in the elderly and very young, H1N1 disproportionately causes severe disease in young adults aged 15 to 45. If a vignette presents a previously healthy 25-year-old with bilateral pneumonia and ARDS, H1N1 should be high on the differential. This reversal of the expected age pattern is a deliberate distractor designed to make students choose atypical pneumonia or autoimmune etiologies instead.

Finally, remember that zanamivir is contraindicated in patients with reactive airway disease. If the patient has a history of asthma and is diagnosed with H1N1, the correct antiviral choice is oseltamivir, not zanamivir. This contraindication appears frequently as a wrong-answer trap in pharmacology-focused questions.

The core competency being tested across all H1N1 questions is the ability to recognize a viral pneumonia pattern in a young, otherwise healthy patient, initiate timely antiviral therapy without waiting for confirmatory results, and manage respiratory complications using evidence-based critical care principles.